Preclinical and Clinical Development of Camptothecins-Reference-Cited by-同舟云学术

Preclinical and Clinical Development of Camptothecins

Published:1994 Issue: Volume: Page:51-72
ISSN:1054-3589
Container-title:DNA Topoisomerases: Topoisomerase-Targeting Drugs
language:
Short-container-title:

Author:

Costin Dan,Potmesil Milan

Publisher

Elsevier

Reference106 articles.

1. Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin;Abelson;Nature (London) New Biol.,1972

2. High dose intensity of CPT-11 administered as single dose every 3 weeks: The Institut Gustave Roussy experience;Abigerges;Proc. Am. Soc. Clin. Oncol.,1993

3. Clinical significance of P-glycoprotein in multidrug resistance malignancies;Arceci;Blood,1993

4. Plant anticancer agents. XXI. Constituents of Merrilliodendron megacarpum;Arisawa;Planta Med.,1981

5. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells;Bertrand;Eur. J. Cancer,1992

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials;Clinical Oncology;2024-02

2. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear;Therapeutic Advances in Medical Oncology;2024-01

3. Design, synthesis and biological evaluation of 1,3-diphenylbenzo[f][1,7]naphthyrdines;Bioorganic & Medicinal Chemistry;2017-10

4. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients;Cancer Chemotherapy and Pharmacology;2015-01-11

5. Cancer Drugs;Drug Discovery;2013-04-09